In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species

Medical Mycology

Volumn 43, Issue 2, 2005, Pages 179-185

  Gupta, Aditya K ^a,b   Kohli, Y ^b   Batra, R ^b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

Author keywords

Antifungals; Dermatophytes; Minimum inhibitory concentrations (MIC)

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; RAVUCONAZOLE; TERBINAFINE;

ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DERMATOPHYTE; DILUTION; DRUG SENSITIVITY; EPIDERMOPHYTON FLOCCOSUM; FUNGUS ISOLATION; HUMAN; IN VITRO STUDY; MICROSPORUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TRICHOPHYTON; YEAST;

ANTIFUNGAL AGENTS; ARTHRODERMATACEAE; FLUCONAZOLE; FUNGI; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; MYCOSES; NAPHTHALENES; THIAZOLES; TRIAZOLES; YEASTS;

ARTHRODERMATACEAE; EPIDERMOPHYTON; MICROSPORUM; TRICHOPHYTON;

EID: 15944366860     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/13693780410001731583     Document Type: Article

References (27)

1. Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev 1995; 8: 240-259.
2. Gupta AK, Del Rosso JQ. An evaluation of intermittent therapies used to treat onychomycosis and other dermatomycoses with the oral antifungal agents. Int J Dermatol 2000; 39: 401-411.
3. Macura AB. Dermatophytes, pathogens or saprophytes. Int J Dermatol 2003; 34: 529-530,
4. Roberts DT. Onychomycosis: current treatment and future challenges. Br J Dermatol 1999: 141: 1-4.
5. Rex JH, Pfaller MA, Walsh TJ, et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001; 14: 643-658.
6. Barchiesi F, Arzeni D, Camiletti V, et al. In vitro activity of posaconazole against clinical isolates of dermatophytes. J Clin Microbiol 2001; 39: 4208-4209.
7. Barchiesi F, Caggiano G, Maracci M, et al. Antifungal susceptibility patterns of yeast isolates causing bloodstream infections. J Antimicrob Chemother 2003; 51: 431-433.
8. Barchiesi F, Schimizzi AM, Caselli F, et al. Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans. J Antimicrob Chemother 2001; 48: 769-773.
9. Cacciapuoti A, Loebenberg D, Corcoran E, et al. In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother 2000; 44: 2017-2022.
10. Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003; 51: 45-52.
11. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743, 872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36: 2950-2956.
12. Pfaller MA, Messer SA, Hollis RJ, Jones RN. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother 2001; 45: 2862-2864.
13. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002; 46: 1581-1582.
14. Yamazumi T, Pfaller MA, Messer SA, et al. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans. Antimicrob Agents Chemother 2000; 44 2883-2886.
15. National Committee for Clinical Laboratory Standards. Reference methodfor broth dilution antifungal susceptibility testing of yeasts. Approved Standard; document no. M27-A. Wayne, PA: NCCLS, 1997.
16. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Proposed Standard; document no. M38-P. Wayne, PA: NCCLS, 1998.
17. Jessup CJ, Warner J, Isham N. Antifungal susceptibility testing of dermatophytes: establishing a medium for inducing conidial growth and evaluation of susceptibility of clinical isolates. J Clin Microbiol 2000; 38: 341-344.
18. Norris HA, Elewski BE, Ghannoum MA. Optimal growth conditions for the determination of the antifurgal susceptibility of three species of dermatophytes with the use of a microdilution method. J Am Acad Dermatol 1999; 40: S9-S13.
19. Pfaller MA, Diekema DJ, Jones RN, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001; 39: 3254-3259.
20. Cohen JA. Power primer. Psychol Bull 1992; 112: 155-159.
21. Fernandez-Torres B, Carrillo ME, Del Palacio A, et al. In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrob Agents Chemother 2001; 45: 2524-2528.
22. Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus species and other filamentous fungi. Report from SENTRY Antimicrobial Surveillance Program 2000. Antimicrob Agents Chemother 2002; 46: 1032-1037.
23. Waller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ. Trends in antifungal susceptibility of Candida species isolated from pediatric and adult patients with bloodstream infections. Report from SENTRY Antimicrobial Surveillance Program 1997 to 2000. J Clin Microbiol 2002; 40: 852-856.
24. Laverdiere M, Hoban D, Restieri C, Habel F. In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother 2002; 50: 119-123.
25. Perea S, Gonzalez G, Fothergill AW. Sutton DA, Rinaldi MG. In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles. J Clin Microbiol 2002; 40: 1831-1833.
26. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12: 40-79.
27. Roberts J, Schock K, Marino S, Andriole VT. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366 in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 2000; 44: 3381-3388.